Media & Investors

Investor Alerts

May 18, 2020

Akcea Announces Appointment of New Chief Financial Officer

Michael D. Price brings more than 25 years of experience in the pharmaceutical industry, including in the rare disease sector

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Michael D. Price has joined the company as executive vice president and...
May 14, 2020

Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy

TEGSEDI is the first antisense medicine available to patients in Spain for at-home subcutaneous injection

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced The Ministry of Health of Spain (MSCBS) has granted approval for the...
May 13, 2020

Akcea Therapeutics Canada Confirms Letter of Intent with Pan-Canadian Pharmaceutical Alliance for TEGSEDI™ (inotersen injection)

OTTAWA, ON., - May 13, 2020 (CNW) – Akcea Therapeutics Canada, Inc., a subsidiary of Akcea Therapeutics, Inc. (NASDAQ: AKCA), today announced that it has concluded its negotiation with the...
May 7, 2020

Akcea Expands Leadership Team with Appointment of Carla Poulson as Senior Vice President and Chief Human Resources Officer

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Carla Poulson has joined the company as senior vice president and chief...
- Photos 1
May 5, 2020

Akcea Reports Financial Results and Highlights for First Quarter 2020

Achieved First Quarter 2020 Global Net Product Revenues of $15 Million

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing medicines to treat patients with serious and rare...

Show per page